Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

McKesson
Merck
Johnson and Johnson
Express Scripts
Dow
Harvard Business School

Last Updated: January 27, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Fasudil

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the development status for investigational drug Fasudil?

Fasudil is an investigational drug.

There have been 10 clinical trials for Fasudil. The most recent clinical trial was a Phase 3 trial, which was initiated on July 1st 2019.

The most common disease conditions in clinical trials are Motor Neuron Disease, Amyotrophic Lateral Sclerosis, and Heart Failure. The leading clinical trial sponsors are Shahid Beheshti University of Medical Sciences, Brigham and Women's Hospital, and Colorado State University.

There are eight hundred and forty-one US patents protecting this investigational drug and eight international patents.

Recent Clinical Trials for Fasudil
TitleSponsorPhase
Early Intracoronary Administration of Fasudil in the Primary PCI of ST-segment-Elevation Myocardial InfarctionRenJi HospitalPhase 4
Fasudil Eye Drop in Retinopathy Of Prematurity(ROP)Shahid Beheshti University of Medical SciencesPhase 2/Phase 3
Inhibition of Rho Kinase (ROCK) With Fasudil as Disease-modifying Treatment for ALSUniversity Medical Center GoettingenPhase 2

See all Fasudil clinical trials

Clinical Trial Summary for Fasudil

Top disease conditions for Fasudil
Top clinical trial sponsors for Fasudil

See all Fasudil clinical trials

US Patents for Fasudil

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Fasudil   Start Trial Ethylsulfonated hyaluronic acid biopolymers and methods of use thereof The Regents of the University of California (Oakland, CA)   Start Trial
Fasudil   Start Trial Use of anthelmintic agents against Dirofilaria immitis Intervet Inc. (Madison, NJ)   Start Trial
Fasudil   Start Trial Diarylimidazole compound and harmful organism control agent Nippon Soda Co., Ltd. (Tokyo, JP)   Start Trial
Fasudil   Start Trial Minimal volume reprogramming of mononuclear cells Fate Therapeutics, Inc. (San Diego, CA)   Start Trial
Fasudil   Start Trial Alkynyl pyridine-substituted amide compound and pesticide Nissan Chemical Industries, Ltd. (Chiyoda-ku, JP)   Start Trial
Fasudil   Start Trial Corneal thickness modulating agent KOWA COMPANY, LTD. (Nagoya-shi, JP)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Fasudil

Drugname Country Document Number Estimated Expiration Related US Patent
Fasudil European Patent Office 2981556 2033-04-02   Start Trial
Fasudil World Intellectual Property Organization (WIPO) 2014165513 2033-04-02   Start Trial
Fasudil Australia 2015286634 2034-07-11   Start Trial
Fasudil Brazil 112017000398 2034-07-11   Start Trial
Fasudil China 106659720 2034-07-11   Start Trial
Fasudil European Patent Office 3177291 2034-07-11   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
McKesson
Mallinckrodt
McKinsey
AstraZeneca
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.